Johnson & Johnson $JNJ Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 118,282 shares of the company’s stock after selling 2,591 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Johnson & Johnson were worth $21,931,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SOA Wealth Advisors LLC. boosted its stake in Johnson & Johnson by 0.7% during the third quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after buying an additional 53 shares during the last quarter. Ethos Financial Group LLC increased its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock valued at $1,689,000 after purchasing an additional 53 shares during the last quarter. Heritage Oak Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 3.5% during the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock valued at $304,000 after acquiring an additional 55 shares during the period. Investor s Fiduciary Advisor Network LLC grew its holdings in shares of Johnson & Johnson by 0.8% in the third quarter. Investor s Fiduciary Advisor Network LLC now owns 6,905 shares of the company’s stock valued at $1,280,000 after purchasing an additional 55 shares in the last quarter. Finally, TPG Advisors LLC boosted its position in Johnson & Johnson by 3.5% in the 3rd quarter. TPG Advisors LLC now owns 1,628 shares of the company’s stock valued at $302,000 after buying an additional 55 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $245.32 on Thursday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $223.12 and its 200 day moving average price is $200.79. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $247.25. The firm has a market cap of $591.19 billion, a price-to-earnings ratio of 22.20, a price-to-earnings-growth ratio of 2.39 and a beta of 0.35.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is 47.06%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong product momentum: J&J’s oncology franchise (Darzalex) and new data for Tremfya are driving revenue upside and underpinning investor confidence in sustainable growth. Can J&J Sustain Its Double-Digit Oncology Growth Streak?
• Positive Sentiment: FDA filing for a rare-disease drug: J&J submitted an sBLA for IMAAVY (nipocalimab) as a first-ever treatment for wAIHA — approval would add a high-value orphan indication and expand the pipeline. PR Newswire: J&J seeks FDA approval of IMAAVY
• Positive Sentiment: Strategic pivot and MedTech tailwinds: Coverage highlights J&J’s shift into higher-margin medical devices, robotics and Shockwave/IVL tech, supporting margin expansion and a path to ~$100B revenue guidance. Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
• Positive Sentiment: Potential DePuy Synthes divestiture: Reports that J&J is exploring a major sale of its orthopedics unit could unlock significant cash and simplify the business, a clear value-creation catalyst if executed. J&J Eyes Mega Sale Of DePuy Synthes
• Neutral Sentiment: Analyst moves and valuation tweaks: Street price targets have been nudged modestly higher, but changes are incremental — supportive but not a strong directional signal. How Shifting Analyst Targets Are Rewriting The J&J Investment Story
• Neutral Sentiment: Corporate tech & partnerships story: Reports on J&J’s enterprise tech investments and a first co-funding with Blackstone highlight long-term transformation, but near-term financial impact is unclear. Enterprise Technology Analysis Report
• Negative Sentiment: Bayer lawsuit and legal overhang: Bayer sued over survival-claim marketing for a prostate cancer drug, adding litigation risk and headline volatility for Janssen’s oncology unit. Bayer files lawsuit against J&J
• Negative Sentiment: Insider selling: EVP Timothy Schmid disclosed sales totaling thousands of shares in recent filings — routine but sometimes perceived negatively as profit-taking. SEC Form 4: Timothy Schmid

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,251,310.02. This trade represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 30,142 shares of company stock worth $7,360,528. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JNJ shares. Barclays raised their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a report on Tuesday, December 30th. The Goldman Sachs Group restated a “buy” rating and set a $250.00 target price on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $240.00 to $255.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Finally, Morgan Stanley set a $262.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a report on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $232.70.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.